Last updated: November 07, 2021

CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD²) Network, a functional genomics initiative, bridges the gap between genomics and development of effective therapeutics. The Network aims to understand tumor development, heterogeneity, drug resistance, and metastasis to develop optimal combinations of chemotherapy with immunotherapy.

Banner for CTD squared program. Links to CTD squared program page

News & Publications

View In the News Page

CTD²

February 01, 2023

Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia

Drug resistance in chronic myeloid leukaemia (CML) may occur via mutations in the causative BCR::ABL1 fusion or BCR::ABL1-independent mechanisms. We analysed 48 patients with BCR::ABL1-independent resistance for the presence of secondary fusion genes by RNA sequencing. We identified 10 of the...

CTD²

January 04, 2023

Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts

Purpose: The liver is the most frequent metastatic site for colorectal cancer. Its microenvironment is modified to provide a niche that is conducive for colorectal cancer cell growth. This study focused on characterizing the cellular changes in the metastatic colorectal cancer (...

CTD²

November 14, 2022

OncoLoop: A network-based precision cancer medicine framework

Prioritizing treatments for individual cancer patients remains challenging, and performing co-clinical studies using patient-derived models in real-time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity in...

CTD²

November 14, 2022

Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma

Checkpoint inhibition immunotherapy has revolutionized cancer treatment, but many patients show resistance. Here we perform integrative transcriptomic and proteomic analyses on emerging immuno-oncology targets across multiple clinical cohorts of melanoma under anti-PD-1 treatment, on both bulk...

CTD²

October 14, 2022

Cellular barcoding to decipher clonal dynamics in disease

Cellular barcodes are distinct DNA sequences that enable one to track specific cells across time or space. Recent advances in our ability to detect natural or synthetic cellular barcodes, paired with single-cell readouts of cell state, have markedly increased our knowledge of clonal dynamics and...